Biohaven is up 19.9%, or $3.52 to $21.17.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHVN:
- Biohaven completes enrollment in Phase 3 study of taldefgrobep alfa
- Biohaven announces results from Phase 1 EEG study of BHV-7000
- Biohaven says taldefgrobep alfa receives EU orphan drug designation for SMA
- Biohaven reports Q2 EPS ($1.25), consensus ($1.21)
- Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments